Table 1

Clinical and demographic features of NHL patients
NHL subtypes Total
BL DLBCL NHL-NOS
Number of cases 32/35 (91.4%) 2/35 (5.7%) 1/35 (2.9%) 35/35 (100%)
Age
1-4 5/32 (15.6%) 0/2 (0%) 0/1 (0%) 5/35 (14.3%)
5-9 21/32 (65.6%) 2/2 (100%) 1/1 (100%) 24/35 (68.6%)
10-15 6/32 (18.8%) 0/2 (0%) 0/1 (0%) 6/35 (17.1%)
Sex
Male 14/32 (43.8%) 0/2 (0%) 0/1 (0%) 14/35 (40%)
Female 18/32 (56.2%) 2/2 (100%) 1/1 (100%) 21/35 (60%)
Primary tumour site
Jaw 16/32 (50%) 0/2 (0%) 0/1 (0%) 16/35 (45.7%)
Abdomen 16/32 (50%) 0/2 (0%) 0/1 (0%) 16/35 (45.7%)
Lymph Node 0/32 (0%) 2/2 (100%) 1/1 (100%) 3/35 (8.6%)
CNS involvement 1/32 (3.1%) 0/2 (0%) 0/1 (0%) 1/35 (2.9%)
aBone marrow involvement 0/11 (0%) 0/11 (0%) 1/11 (9.1%) 1/11 (9.1%)
Fever 9/32 (28.1%) 1/2 (50%) 1/1 (100%) 11/35 (31.4%)
Anaemia 26/32 (81.3%) 1/2 (50%) 1/1 (100) 28/35 (80%)
Clinical stage
Early (I/II) 19/32 (59.3%) 0/2 (0%) 0/1 (0%) 19/35 (54.3%)
Late (III/IV) 13/32 (40.7%) 2/2 (100%) 1/1 (100%) 16/35 (45.6%)

a Bone marrow sampling was done in 11 only cases because of unavailability of facilities in two study sites.

Kabyemera et al.

Kabyemera et al. BMC Pediatrics 2013 13:4   doi:10.1186/1471-2431-13-4

Open Data